

Remarks

Currently Claims 1-4, 6-8, 10-11, 14-26 are pending. Claims 5, 9 and 12-13 are cancelled. Claims 1-3, 6-8, and 10-11 are amended. Claims 14-26 are added.

The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 1-3 are amended to change "or" to "and" and to remove the "such as" clause. Claims 2-3 are further amended to place the claims in independent form. Claims 6-8 and 10-11 are amended to remove a redundant expression. Claims 7-8 and 10-11 are further amended to remove multiple dependency for the purpose of reducing claim fees. Claims 10-11 are further amended to remove human subject, which is now recited in new claims 14-15. The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability. No new matter is added.

Support for new claims 14-26 can be found throughout Applicant's original specification, including at original claims 10-11 and pages 14-16. No new matter is added.

Notice of Co-pending Applications

The Examiner is requested to please take note of the following co-pending applications which are commonly owned.

Serial No.	Filing Date
10/362,745	6/25/2003
10/477546	11/13/2003
10/477819	4/27/2004
10/486,001	7/29/2004
10/477547	4/27/2004

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is

invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan  
Attorney for Applicants  
Registration No. 38,181

*March*  
Date: 15 February, 2005  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988